Abstract: Methods and systems provide for using echo measurements, to detect cable faults in cables of vehicular communication networks.

Abstract: Methods and systems are provided for fault diagnosis in a vehicular communication network. The methods and systems utilize a trained neural network model which is downloaded to a local computer associated with the vehicular communication network of a given vehicle and which applies inputs from the given vehicle to output maintenance recommendations for the given vehicle.

Abstract: The present application provides a structure of HR-SOI embedded with a charge capture layer and manufacture thereof. The process for manufacturing a structure of HR-SOI embedded with a charge capture layer comprises: providing a first substrate, wherein the first substrate has a first surface to be subjected to a roughness treatment to form an uneven morphology on the first surface; forming a surface treatment layer, wherein the surface treatment layer has an uneven surface morphology; and forming a polysilicon layer on the surface treatment layer. By the roughness treatment to the first substrate, the first surface and the surface treatment layer both have uneven surface morphology, such that the formed polysilicon layer has stable orientation evolution and grain size, and an increased grain boundary density. Thereby a highly efficient charge trapping polysilicon film can be obtained.

Abstract: The present application provides a structure of HR-SOI embedded with a charge capture layer and manufacture thereof. The process for manufacturing a structure of HR-SOI embedded with a charge capture layer comprises: providing a first substrate, wherein the first substrate has a first surface, and a pinning layer is formed on the first surface by a deposition process, and homogenizing the pinning layer surface by dry etching to adjust a thickness uniformity of the pinning layer. Accordingly, the thickness uniformity of the obtained polysilicon film is able to reach a good state.

Abstract: Provided are a method and a system for image batch processing recognition. Improved adaptive threshold segmentation, regional growth segmentation and global threshold segmentation methods are used to recognize red sandstone samples in a process of uniaxial compression failure in a certain area of Yunnan. In an embodiment, batch recognition times and relative errors of partial recognition images are calculated.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Abstract: A light-emitting device and method for using quantum dot LEDs are provided in the present application. The light-emitting device includes at least one quantum dot LED, wherein the quantum dot LED includes a first electrode, an electron transport layer, a quantum dot layer, a hole transport layer, and a second electrode which are sequentially stacked; a fluorescence quantum yield of quantum dots in the quantum dot layer is equal to or greater than 50%; a ratio of an average photon voltage to an operating voltage of the quantum dot LED is equal to or greater than 1; electroluminescence of the quantum dot LED includes thermoelectrically-assisted up-conversion luminescence. The quantum dot LED can achieve higher external power conversion efficiency in the light-emitting device.

Abstract: A method is provided that includes: obtaining playback behavior data of a video to be processed; determining, based on the playback behavior data, a target video segment in which a content segmentation point of the video is located; extracting an audio feature of the target video segment; and determining the content segmentation point from the target video segment based on the audio feature.

Abstract: Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.

Abstract: According to a first aspect, the present disclosure relates to a semiconductor sub-assembly comprising a semiconductor device comprising: a semi-insulating substrate (201); a first section (210) configured to emit light; at least a second section (220) configured to modulate light emitted by said first section (210); wherein said first section (210) and said at least second section (220) are monolithically integrated on said semi-insulating substrate (201) and have a common optical waveguide (205?); said first section (210) forms a first vertical PIN junction with a first electrode (212) and a second electrode (214) on said semi-insulating substrate (201); said second section (220) forms a second vertical PIN junction with a first electrode (222) and a second electrode (224) on said semi-insulating substrate (201); an electric resistance between said first electrode (212) of said first section (210) and said first electrode (222) of said second section (220) is superior to about 50 ohms; and an electric resis

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are compounds, crystalline free forms, crystalline salt forms, and pharmaceutical compositions of Compound 1. Also provided are methods of preparing and methods of using the same, e.g., for inhibiting a kinase and/or for treating various diseases or disorders, such as autoimmune diseases.

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.